AIMC Topic: Lactams, Macrocyclic

Clear Filters Showing 1 to 5 of 5 articles

Deep-learning based repurposing of FDA-approved drugs against dihydrofolate reductase and molecular dynamics study.

Journal of biomolecular structure & dynamics Apr 21, 2021
causes the fatal fungal bloodstream infection in humans called Candidiasis. Most of the species are resistant to the antifungals used to treat them. Drug-resistant poses very serious public health issues. To overcome this, the development of effec...
Candidiasis Antifungal Agents Molecular Dynamics Simulation Sulfonamides United States Candida albicans Cyclopropanes Drug Repositioning United States Food and Drug Administration Proline Lactams, Macrocyclic Drug Approval Aminopyridines Tetrahydrofolate Dehydrogenase Rifampin Benzodioxoles Humans Folic Acid Antagonists Molecular Docking Simulation Deep Learning
View on PubMed DOI

Ritonavir-boosted paritaprevir, ombitasvir plus ribavirin could improve eGFR in patients with renal impairment and HCV: an Egyptian cohort.

Expert review of gastroenterology & hepatology Nov 13, 2018
BACKGROUND: The present study aimed at evaluation of changes in estimated glomerular filtration rate (eGFR) among chronic Hepatitis C virus (HCV) patients with chronic kidney disease (CKD) Stages 3-5 who were treated with 12 weeks of ritonavir-booste...
Renal Dialysis Viral Load Sulfonamides Time Factors Young Adult Hepacivirus Genotype Antiviral Agents Adult Proline Kidney Male Drug Therapy, Combination Lactams, Macrocyclic Humans Renal Insufficiency, Chronic Middle Aged Macrocyclic Compounds Glomerular Filtration Rate Prospective Studies Hepatitis C, Chronic Treatment Outcome Ribavirin Valine Female Cyclopropanes Sustained Virologic Response Aged Anilides Recovery of Function Carbamates Egypt
View on PubMed DOI

Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial.

The lancet. Gastroenterology & hepatology Jun 16, 2016
BACKGROUND: In Egypt, chronic hepatitis C virus (HCV) infection occurs in around 10% of the population (about 8 million individuals), and is a leading cause of liver cirrhosis, hepatocellular carcinoma, and mortality. Although HCV genotype 4 constitu...
Macrocyclic Compounds Ribavirin Sustained Virologic Response Ritonavir Drug Therapy, Combination Hepatitis C, Chronic Valine Drug Administration Schedule Anilides Carbamates Lactams, Macrocyclic Sulfonamides Hepacivirus Administration, Oral Proline Treatment Outcome Follow-Up Studies Cyclopropanes Egypt Aged, 80 and over Young Adult Adult Male Antiviral Agents Genotype Liver Cirrhosis Middle Aged Adolescent Humans Female Aged
View on PubMed DOI

Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial.

The lancet. Gastroenterology & hepatology Jun 16, 2016
BACKGROUND: Hepatitis C virus (HCV) genotype 4 infection is most commonly reported in sub-Saharan Africa and the Middle East; however, prevalence is increasing worldwide through immigration. HCV genotype 4 accounts for 20% of all infections, but clin...
Female Aged Aged, 80 and over Young Adult Humans Antiviral Agents Genotype Treatment Outcome Follow-Up Studies Cyclopropanes Adult Male Middle Aged Adolescent Anilides Carbamates Lactams, Macrocyclic Macrocyclic Compounds Drug Therapy, Combination Ribavirin Hepatitis C, Chronic Sulfonamides Sustained Virologic Response Valine Hepacivirus Drug Administration Schedule Proline Ritonavir
View on PubMed DOI

[A real-world study of paritaprevir/ritonavir-ombitasvir combined with dasabuvir in the treatment of genotype 1b chronic hepatitis C].

Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology Dec 20, 2018
To recognize the efficacy and safety of paritaprevir/ritonavir-ombitasvir combined with dasabuvir (OBV/PTV/RTV+DSV) in the treatment of genotype 1b chronic hepatitis C. Patients with genotype 1b chronic hepatitis C who were admitted to the People's...
Hepacivirus Proline Ritonavir Drug Therapy, Combination Hepatitis C, Chronic Valine Anilides Carbamates Genotype Humans Treatment Outcome Cyclopropanes Sulfonamides Male Middle Aged Uracil Lactams, Macrocyclic China Macrocyclic Compounds Antiviral Agents Ribavirin 2-Naphthylamine
View on PubMed DOI
Popular Topics
Recent Journals